卵巢癌患者血清和腹水中树突状细胞相关miRNA水平分析

发布时间：2018-01-20 02:52

  本文关键词： 卵巢癌 微小RNA 腹水 血清 免疫状态　出处：《细胞与分子免疫学杂志》2015年03期 　论文类型：期刊论文

【摘要】：目的观察卵巢癌患者血清标本中与树突状细胞分化发育调控有关的miRNA水平及其与临床特征的关系,探讨血清中miRNA的检测在卵巢癌免疫状态及预后判断中的价值。方法采用实时荧光定量PCR技术检测39例卵巢癌患者腹水和血清及20例健康女性成年人血清中miRNA的水平。结果卵巢癌患者血清中miR-21、miR-222和miR-142-3p水平显著高于健康对照组,在临床Ⅲ~Ⅳ期卵巢癌患者血清中miR-21水平高于Ⅰ~Ⅱ期,病理分级高的卵巢癌患者血清中miR-142-3p水平低于低级别的患者,而且患者腹水中miR-21和miR-222的水平高于外周血。结论卵巢癌患者血清和腹水miR-21、miR-222和miR-142-3p水平升高,与临床分期病理分级有关。
[Abstract]:Objective to observe the level of miRNA and its relationship with clinical features in serum samples of ovarian cancer patients related to the regulation of dendritic cell differentiation and development. To evaluate the value of serum miRNA in the immune status and prognosis of ovarian cancer methods Real-time quantitative PCR technique was used to detect ascites and serum of 39 patients with ovarian cancer and 20 healthy women. Results the serum level of miR-21 in patients with ovarian cancer. The levels of miR-222 and miR-142-3p were significantly higher than those of healthy controls. The serum miR-21 levels in patients with stage 鈪，

本文编号：1446553